Japan » Business Opportunities » Mfg. Collaborations ::
(1) Experience with
Manufacturing Collaboration :
We have
collaborated with various companies worldwide and
all such projects have been successful. One such
success story is our collaboration with Novo
Nordisk, one of the largest manufacturers of
Insulins, worldwide.
We have been manufacturing Insulin for Novo
Nordisk’s India requirement for more than 15 years
now. Our parenteral site for insulin production is
dedicated for Novo Nordisk products, and complies
with their worldwide norms. On numerous occasions,
we have won the award for Best Maintained
Manufacturing Site of Novo Nordisk worldwide.
The collaboration was recently extended for a
longer term, for Novo Nordisk’s new and existing
range of products in India. For this purpose, a
new, dedicated formulation and packaging facility
for Insulin is being established at our existing
manufacturing facility at Indrad, Gujarat,
exclusively for Novo Nordisk. This new facility
will have the requisite flexibility to expand and
the production will be done with the same state of
the art technology and quality standards as
practiced across the world by Novo Nordisk.
(2) Contract
Manufacturing :
Our manufacturing
facilities are up to the world-class standards and
comply with most stringent norms, both internal
and regulatory. At present, we manufacture
products for more than 50 countries, and are
awaiting US FDA approval.
Given the cost pressures in the generics market
worldwide, especially the USA, you may wish to
transfer your manufacturing operations to
cost-competitive, high quality, reliable sources.
We invite you to transfer the manufacturing of
your products to our facility.
Our facilities already have in place, machines
which can handle manufacturing of a variety of
oral solid dosage formulations. However, if
required, we are ready to invest in additional
capabilities and machineries as required by our
partner to ensure smooth and stable supply of
products, which meet the regulatory and in-house
requirements.
Torrent has already undertaken the construction
of a new facility to cater to Novo Nordisk’s
increased requirements for India.
(3) API for Sale
:
Our Active Pharmaceutical Ingredient
(API) facility, located at our existing plant at
Indrad, manufactures API for both in-house
consumption and sale. You are welcome to take
advantage of our facility in India for your
worldwide requirements.
The APIs are of high quality; the plant has
been approved by many regulatory authorities
including the MHRA (UK). Some DMFs have already
been submitted to the US FDA, and the plant
inspection is awaited.
(4) Contact Us :
Mr. Toshimitsu
Kurogi
Representative Director
Torrent
Pharma Japan Co. Ltd.
SOHO STATION 1003
24-8
Yamashita-cho, Naka-ku
Yokohama, 231-0023,
JAPAN.
|
